Anemia, Sickle Cell
Conditions
Interventions
This is a randomized, double-blind, placebo-controlled clinical study with two arms. Study group: 50 patients with Sickle Cell Anemia using Hydroxyurea (dose greater than or equal to 500 mg per day) w
Sponsors
Secretaria da Saude do Estado do Ceara
Universidade Federal do Ceará
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients with Sickle Cell Anemia; age 18 or over; of both sexes; taking hydroxyurea (dose equal to or greater than 500mg/day)
Exclusion criteria
Exclusion criteria: Patients who have undergone transfusion therapy in the last three months; patients using iron chelators or antioxidant vitamins; smokers; alcoholics; pregnant women; with Diabetes mellitus; renal and/or hepatic insufficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to determine the efficacy of L-arginine in reducing recurrent vaso-occlusion crises in patients with Sickle Cell Anemia. Data collected before, during and after the intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of improvements in the quality of life of patients with sickle cell anemia, using questionnaires such as SF-36 or EuroQol-5D.;Increased fetal hemoglobin (HbF) levels.;Reduction in levels of pro-inflammatory cytokines and increase in anti-inflammatory cytokines.;Increased of nitric oxide levels.;Decreased levels of arginase and increased levels of arginina. ;Decreased levels of hepcidine. | — |
Countries
Brazil
Contacts
Public ContactRomélia Lemes
Universidade Federal do Ceará
Outcome results
None listed